Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
44.56
+0.70 (1.60%)
Jul 26, 2024, 4:30 PM EDT - Market closed
Celldex Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 - 2013 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.07 | 6.88 | 2.36 | 4.65 | 7.42 | 3.57 | Upgrade
|
| Revenue Growth (YoY) | 92.76% | 192.02% | -49.32% | -37.30% | 107.61% | -62.54% | Upgrade
|
| Cost of Revenue | 122.87 | 118.01 | 82.26 | 53.31 | 42.53 | 42.67 | Upgrade
|
| Gross Profit | -116.8 | -111.13 | -79.9 | -48.66 | -35.12 | -39.1 | Upgrade
|
| Selling, General & Admin | 33.38 | 30.91 | 27.2 | 20.49 | 14.46 | 15.43 | Upgrade
|
| Operating Expenses | 33.38 | 30.91 | 27.2 | 20.49 | 14.46 | 15.43 | Upgrade
|
| Operating Income | -150.18 | -142.04 | -107.1 | -69.15 | -49.57 | -54.53 | Upgrade
|
| Interest & Investment Income | 17.8 | 13.11 | 2.91 | 0.51 | 2.41 | 4.15 | Upgrade
|
| EBT Excluding Unusual Items | -132.38 | -128.93 | -104.19 | -68.64 | -47.17 | -50.37 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -1.8 | Upgrade
|
| Legal Settlements | -12.5 | -12.5 | -15 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | 6.86 | 1.41 | 4.22 | 1.29 | Upgrade
|
| Pretax Income | -144.88 | -141.43 | -112.33 | -70.74 | -60.95 | -50.88 | Upgrade
|
| Income Tax Expense | - | - | - | -0.23 | -1.17 | - | Upgrade
|
| Net Income | -144.88 | -141.43 | -112.33 | -70.51 | -59.78 | -50.88 | Upgrade
|
| Net Income to Common | -144.88 | -141.43 | -112.33 | -70.51 | -59.78 | -50.88 | Upgrade
|
| Shares Outstanding (Basic) | 51 | 48 | 47 | 43 | 30 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 48 | 47 | 43 | 30 | 15 | Upgrade
|
| Shares Change (YoY) | 9.27% | 3.33% | 9.37% | 44.64% | 104.32% | 38.93% | Upgrade
|
| EPS (Basic) | -2.82 | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 | Upgrade
|
| EPS (Diluted) | -2.82 | -2.92 | -2.40 | -1.64 | -2.02 | -3.51 | Upgrade
|
| Free Cash Flow | -120.94 | -109.11 | -105.56 | -62.16 | -41.96 | -47.15 | Upgrade
|
| Free Cash Flow Per Share | -2.35 | -2.25 | -2.25 | -1.45 | -1.42 | -3.25 | Upgrade
|
| Operating Margin | -2473.30% | -2063.66% | -4543.74% | -1486.73% | -668.27% | -1526.03% | Upgrade
|
| Free Cash Flow Margin | -1991.72% | -1585.20% | -4478.57% | -1336.44% | -565.60% | -1319.51% | Upgrade
|
| EBITDA | -147.12 | -139.03 | -104.2 | -66.08 | -45.64 | -49.67 | Upgrade
|
| D&A For EBITDA | 3.06 | 3.01 | 2.9 | 3.07 | 3.93 | 4.86 | Upgrade
|
| EBIT | -150.18 | -142.04 | -107.1 | -69.15 | -49.57 | -54.53 | Upgrade
|
| Revenue as Reported | 6.07 | 6.88 | 2.36 | 4.65 | 7.42 | 3.57 | Upgrade
|
Source: S&P Capital IQ. Standard template.